Prevention of Obesity and Insulin Resistance in Mice Lacking Plasminogen Activator Inhibitor 1

Diabetes

Volumn 53, Issue 2, 2004, Pages 336-346

  Ma, Li Jun ^a   Mao, Su Li ^a   Taylor, Kevin L ^a   Kanjanabuch, Talerngsak ^a   Guan, YouFei ^a   Zhang, YaHua ^a   Brown, Nancy J ^a   Swift, Larry L ^a   McGuinness, Owen P ^b   Wasserman, David H ^b   Vaughan, Douglas E ^a   Fogo, Agnes B ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; GLUCOSE; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLASMINOGEN ACTIVATOR INHIBITOR 1; UNCOUPLING PROTEIN 3;

ADIPOSE TISSUE CELL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CARBOHYDRATE DIET; CONTROLLED STUDY; DRUG MECHANISM; DRUG RECEPTOR BINDING; ENERGY EXPENDITURE; FIBROSIS; GLUCOSE TRANSPORT; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID DIET; LIPID METABOLISM; MALE; METABOLIC RATE; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOSIS; WHITE ADIPOSE TISSUE; WILD TYPE;

ADIPONECTIN; ANIMALS; BLOOD GLUCOSE; CALORIMETRY, INDIRECT; CARRIER PROTEINS; DISEASE MODELS, ANIMAL; GLUCOSE CLAMP TECHNIQUE; HYPERINSULINISM; INSULIN; INSULIN RESISTANCE; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; ION CHANNELS; MALE; MEMBRANE PROTEINS; MICE; MICE, KNOCKOUT; MITOCHONDRIAL PROTEINS; OBESITY; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMERASE CHAIN REACTION; PROTEINS; RNA, MESSENGER; TRANSCRIPTION, GENETIC; TRIGLYCERIDES; WEIGHT GAIN;

EID: 10744228409     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.53.2.336     Document Type: Article

References (83)

1. Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH: The disease burden associated with overweight and obesity. JAMA 282:1523-1529, 1999
2. Marx J: Unraveling the causes of diabetes. Science 296:686-689, 2002
3. Skyler JS, Oddo C: Diabetes trends in the USA. Diabetes Metab Res Rev 18 (Suppl. 3):S21-S26, 2002
4. Collins FM: Current treatment approaches to type 2 diabetes mellitus: successes and shortcomings. Am J Manag Care 8:S460-S471, 2002
5. Fogo AB: The role of angiotensin II and plasminogen activator inhibitor-1 in progressive glomerulosclerosis. Am J Kidney Dis 35:179-188, 2000
6. Ma L-J, Fogo AB: Angiotensin as inducer of plasminogen activator inhibitor-1 and fibrosis. Contrib Nephrol 135:161-170, 2001
7. Landin K, Stigendahl L, Eriksson E, Krotkiewski M, Risberg B, Tengborn L, Smith U: Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1. Metabolism 39:1044-1048, 1990
8. Vague P, Juhan-Vague I, Aillaud MF, Badier C, Viard R, Alessi MC, Collen D: Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects. Metabolism 35:250-253, 1996
9. Juhan-Vague I, Alessi MC, Morange PE: Hypofibrinolysis and increased PAI-1 are linked to atherothrombosis via insulin resistance and obesity. Ann Med 32 (Suppl. 1):78-84, 2000
10. McCormack LJ, Nagi DK, Stickland MH, Mansfield MW, Mohamed-Ali V, Yudkin JS, Knowler WC, Grant PJ: Promoter (4G/5G) plasminogen activator inhibitor-1 genotype in Pima Indians: relationship to plasminogen activator inhibitor-1 levels and features of the insulin resistance syndrome. Diabetologia 39:1512-1518, 1996
11. Hoffstedt J, Andersson IL, Persson L, Isaksson B, Arner P: The common -675 4G/5G polymorphism in the plasminogen activator inhibitor-1 gene is strongly associated with obesity. Diabetologia 45:584-587, 2002
12. Viitanen L, Pihlajamaki J, Halonen P, Lehtonen M, Kareinen A, Lehto S, Laakso M: Association of angiotensin converting enzyme and plasminogen activator inhibitor-1 promoter gene polymorphisms with features of the insulin resistance syndrome in patients with premature coronary heart disease. Atherosclerosis 157:57-64, 2001
13. Ahima RS, Flier JS: Adipose tissue as an endocrine organ. Trends Endocrinol Metab 11:327-332, 2000
14. Saltiel AR: You are what you secrete. Nat Med 7:887-888, 2001
15. Picard F, Auwerx J: PPAR(gamma) and glucose homeostasis. Annu Rev Nutr 22:167-197, 2002
16. Loskutoff DJ, Fujisawa K, Samad F: The fat mouse: a powerful genetic model to study hemostatic gene expression in obesity/NIDDM. Ann N Y Acad Sci 902:272-281, 2000
17. Alessi MC, Peiretti F, Morange P, Henry M, Nalbone G, Juhan-Vague I: Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes 46:860-867, 1997
18. Festa A, D'Agostino R Jr, Mykkanen L, Tracy RP, Zaccaro DJ, Hales CN, Haffner SM: Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance: the Insulin Resistance Atherosclerosis Study (IRAS). Arterioscler Thromb Vasc Biol 19:562-568, 1999
19. Meigs JB, Mittleman MA, Nathan DM, Tofler GH, Singer DE, Murphy-Sheehy PM, Lipinska I, D'Agostino RB, Wilson PW: Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study. JAMA 283:221-228, 2000
20. Aso Y, Matsumoto S, Fujiwara Y, Tayama K, Inukai T, Takemura Y: Impaired fibrinolytic compensation for hypercoagulability in obese patients with type 2 diabetes: association with increased plasminogen activator inhibitor-1. Metabolism 51:471-476, 2002
21. Gurlek A, Bayraktar M, Kirazli S: Increased plasminogen activator inhibitor-1 activity in offspring of type 2 diabetic patients: lack of association with plasma insulin levels. Diabetes Care 23:88-92, 2000
22. Festa A, D'Agostino R Jr, Tracy RP, Haffner SM: Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the Insulin Resistance Atherosclerosis Study. Diabetes 51:1131-1137, 2002
23. Kerins DM, Hao Q, Vaughan DE: Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV. J Clin Invest 96:2515-2520, 1995
24. Nakamura S, Nakamura I, Ma L-J, Vaughan DE, Fogo AB: Plasminogen activator inhibitor-1 expression is regulated by the angiotensin type 1 receptor in vivo. Kidney Int 58:251-259, 2000
25. Ma L-J, Nakamura S, Whitsitt JS, Marcantoni C, Davidson JM, Fogo AB: Regression of sclerosis in aging by an angiotensin inhibition-induced decrease in PAI-1. Kidney Int 58:2425-2436, 2000
26. Frederich RCJ, Kahn BB, Peach MJ, Flier JS: Tissue-specific nutritional regulation of angiotensinogen in adipose tissue. Hypertension 19:339-344, 1992
27. Ailhaud G, Fukamizu A, Massiera F, Negrel R, Saint-Marc P, Teboul M: Angiotensinogen, angiotensin II and adipose tissue development. Int J Obes Relat Metab Disord 24:S33-S35, 2000
28. Barton M, Carmonab R, Ortmanna J, Kriegerb JE, Traupea T: Obesity-associated activation of angiotensin and endothelin in the cardiovascular system. Int J Biochem Cell Biol 35:826-837, 2003
29. Jones BH, Standridge MK, Taylor JW, Moustaid N: Angiotensinogen gene expression in adipose tissue: analysis of obese models and hormonal and nutritional control. Am J Physiol 273:R236-R242, 1997
30. Bastard JP, Pieroni L: Plasma plasminogen activator inhibitor 1, insulin resistance and android obesity. Biomed Pharmacother 53:455-461, 1999
31. Skurk T, Lee YM, Hauner H: Angiotensin II and its metabolites stimulate PAI-1 protein release from human adipocytes in primary culture. Hypertension 37:1336-1340, 2001
32. Morange PE, Lijnen HR, Alessi MC, Kopp F, Collen D, Juhan-Vague I: Influence of PAI-1 on adipose tissue growth and metabolic parameters in a murine model of diet-induced obesity. Arterioscler Thromb Vasc Biol 20:1150-1154, 2000
33. Schafer K, Fujisawa K, Konstantinides S, Loskutoff DJ: Disruption of the plasminogen activator inhibitor 1 gene reduces the adiposity and improves the metabolic profile of genetically obese and diabetic ob/ob mice. FASEB J 15:1840-1842, 2001
34. Lijnen HR, Maquoi E, Morange P, Voros G, Van Hoef B, Kopp F, Collen D, Juhan-Vague I, Alessi MC: Nutritionally induced obesity is attenuated in transgenic mice overexpressing plasminogen activator inhibitor-1. Arterioscler Thromb Vasc Biol 23:78-84, 2003
35. Surwit RS, Kuhn CM, Cochrane C, McCubbin JA, Feinglos MN: Diet-induced type II diabetes in C57BL/6J mice. Diabetes 37:1163-1167, 1988
36. Fogo AB: Progression and potential regression of glomerulosclerosis (Nephrology Forum). Kidney Int 59:804-819, 2001
37. Folch J, Lees M, Sloane-Stanley GH: A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 226:497-509, 1957
38. Morrison WR, Smith LM: Preparation of fatty acid methyl esters and dimethylacetals from lipids with boron fluoride-methanol. J Lipid Res 5:600-608, 1964
39. Halseth AE, Bracy DP, Wasserman DH: Overexpression of hexokinase II increases insulin and exercise-stimulated muscle glucose uptake in vivo. Am J Physiol 276:E70-E77, 1999
40. Obici S, Wang J, Chowdury R, Feng Z, Siddhanta U, Morgan K, Rossetti L: Identification of a biochemical link between energy intake and energy expenditure. J Clin Invest 109:1599-1605, 2002
41. Kratky D, Strauss JG, Zechner R: Tissue-specific activity of lipoprotein lipase in skeletal muscle regulates the expression of uncoupling protein 3 in transgenic mouse models. Biochem J 355:647-652, 2001
42. Ma LJ, Marcantoni C, Linton MF, Fazio S, Fogo AB: Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats. Kidney Int 59:1899-1910, 2001
43. Hauner H, Entenmann G, Wabitsch M, Gaillard D, Ailhaud G, Negrel R, Pfeiffer EF: Promoting effect of glucocorticoids on the differentiation of human adipocyte precursor cells cultured in a chemically defined medium. J Clin Invest 84:1663-1670, 1989
44. Bjorntorp P, Karlsson M, Pertoft H, Pettersson P, Sjostrom L, Smith U: Isolation and characterization of cells from rat adipose tissue developing into adipocytes. J Lipid Res 19:316-324, 1978
45. Viravaidya K, Shuler ML: Prediction of naphthalene bioaccumulation using an adipocyte cell line model. Biotechnol Prog 18:174-181, 2002
46. Mur C, Arribas M, Benito M, Valverde AM: Essential role of insulin-like growth factor I receptor in insulin-induced fetal brown adipocyte differentiation. Endocrinology 144:581-593, 2003
47. Spiegelman BM, Flier JS: Obesity and the regulation of energy balance. Cell 104:531-543, 2001
48. Tataranni PA, Ravussin E: Variability in metabolic rate: biological sites of regulation. Int J Obes Relat Metab Disord 19 (Suppl. 4):S102-S106, 1995
49. Ravussin E, Lillioja S, Knowler WC, Christin L, Freymond D, Abbott WG, Boyce V, Howard BV, Bogardus C: Reduced rate of energy expenditure as a risk factor for body-weight gain. N Engl J Med 318:467-472, 1988
50. Kozak LP, Harper ME: Mitochondrial uncoupling proteins in energy expenditure. Annu Rev Nutr 20:339-363, 2000
51. Ricquier D, Bouillaud F: Mitochondrial uncoupling proteins: from mitochondria to the regulation of energy balance. J Physiol 529:3-10, 2000
52. Li B, Nolte LA, Ju JS, Han DH, Coleman T, Holloszy JO, Semenkovich CF: Skeletal muscle respiratory uncoupling prevents diet-induced obesity and insulin resistance in mice. Nat Med 6:1115-1120, 2000
53. Clapham JC, Arch JR, Chapman H, Haynes A, Lister C, Moore GB, Piercy V, Carter SA, Lehner I, Smith SA, Beeley LJ, Godden RJ, Herrity N, Skehel M, Changani KK, Hockings PD, Reid DG, Squires SM, Hatcher J, Trail B, Latcham J, Rastan S, Harper AJ, Cadenas S, Buckingham JA, Brand MD, Abuin A: Mice overexpressing human uncoupling protein-3 in skeletal muscle are hyperphagic and lean. Nature 406:415-418, 2000
54. Huppertz C, Fischer BM, Kim YB, Kotani K, Vidal-Puig A, Slieker LJ, Sloop KW, Lowell BB, Kahn BB: Uncoupling protein 3 (UCP3) stimulates glucose uptake in muscle cells through a phosphoinositide 3-kinase-dependent mechanism. J Biol Chem 276:12520-12529, 2001
55. Krook A, Digby J, O'Rahilly S, Zierath JR, Wallberg-Henriksson H: Uncoupling protein 3 is reduced in skeletal muscle of NIDDM patients. Diabetes 47:1528-1531, 1998
56. Shimokawa T, Kato M, Watanabe Y, Hirayama R, Kurosaki E, Shikama H, Hashimoto S: In vivo effects of pioglitazone on uncoupling protein-2 and -3 mRNA levels in skeletal muscle of hyperglycemic KK mice. Biochem Biophys Res Commun 251:374-378, 1998
57. Lopez-Solache I, Marie V, Vignault E, Camirand A, Silva JE: Regulation of uncoupling protein-2 mRNA in L6 myotubules. I. Thiazolidinediones stimulate uncoupling protein-2 gene expression by a mechanism requiring ongoing protein synthesis and an active mitogen-activated protein kinase. Endocrine 19:197-208, 2002
58. Saltiel AR: New perspectives into the molecular pathogenesis and treatment of type 2 diabetes. Cell 104:517-529, 2001
59. Okuno A, Tamemoto H, Tobe K, Ueki K, Mori Y, Iwamoto K, Umesono K, Akanuma Y, Fujiwara T, Horikoshi H, Yazaki Y, Kadowaki T: Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 101:1354-1361, 1998
60. Auwerx J: PPARgamma, the ultimate thrifty gene. Diabetologia 42:1033-1049, 1999
61. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF: A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 270:26746-26749, 1995
62. Hu E, Liang P, Spiegelman BM: AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 271:10697-10703, 1996
63. Kahn BB, Flier JS: Obesity and insulin resistance. J Clin Invest 106:473-481, 2000
64. Statnick MA, Beavers LS, Conner LJ, Corominola H, Johnson D, Hammond CD, Rafaeloff-Phail R, Seng T, Suter TM, Sluka JP, Ravussin E, Gadski RA, Caro JF: Decreased expression of apM1 in omental and subcutaneous adipose tissue of humans with type 2 diabetes. Int J Exp Diabetes Res 1:81-88, 2000
65. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA: Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86:1930-1935, 2001
66. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, Ezaki O, Akanuma Y, Gavrilova O, Vinson C, Reitman ML, Kagechika H, Shudo K, Yoda M, Nakano Y, Tobe K, Nagai R, Kimura S, Tomita M, Froguel P, Kadowaki T: The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7:941-946, 2001
67. Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, Nagaretani H, Furuyama N, Kondo H, Takahashi M, Arita Y, Komuro R, Ouchi N, Kihara S, Tochino Y, Okutomi K, Horie M, Takeda S, Aoyama T, Funahashi T, Matsuzawa Y: Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 8:731-737, 2002
68. Kubota N, Terauchi Y, Yamauchi T, Kubota T, Moroi M, Matsui J, Eto K, Yamashita T, Kamon J, Satoh H, Yano W, Nagai R, Kimura S, Kadowaki T, Noda T: Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 277:25863-25866, 2002
69. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE: The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 7:947-953, 2001
70. Combs TP, Wagner JA, Berger J, Doebber T, Wang WJ, Zhang BB, Tanen M, Berg AH, O'Rahilly S, Savage DB, Chatterjee K, Weiss S, Larson PJ, Gottesdiener KM, Gertz BJ, Charron MJ, Scherer PE, Moller DE: Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization. Endocrinology 143:998-1007, 2002
71. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, Nagaretani H, Matsuda M, Komuro R, Ouchi N, Kuriyama H, Hotta K, Nakamura T, Shimomura I, Matsuzawa Y: PPARγ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50:2094-2099, 2001
72. Czekay RP, Aertgeerts K, Curriden SA, Loskutoff DJ: Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins. J Cell Biol 160:781-791, 2003
73. Deng G, Curriden SA, Hu G, Czekay RP, Loskutoff DJ: Plasminogen activator inhibitor-1 regulates cell adhesion by binding to the somatomedin B domain of vitronectin. J Cell Physiol 189:23-33, 2001
74. Loskutoff DJ, Curriden SA, Hu G, Deng G: Regulation of cell adhesion by PAI-1. APMIS 107:54-61, 1999
75. Lopez-Alemany R, Redondo JM, Nagamine Y, Munoz-Canoves P: Plasminogen activator inhibitor type-1 inhibits insulin signaling by competing with alphavbeta3 integrin for vitronectin binding. Eur J Biochem 270:814-821, 2003
76. Yale JF: Prevention of type 2 diabetes. Int J Clin Pract Suppl 35-39, 2000
77. Fogari R, Mugellini A, Zoppi A, Corradi L, Preti P, Lazzari P, Derosa G: Losartan and perindopril effects on plasma plasminogen activator inhibitor-1 and fibrinogen in hypertensive type 2 diabetic patients. Am J Hypertens 15:316-320, 2002
78. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, Luomanmaki K, Dahlof B, de Faire U, Morlin C, Karlberg BE, Wester PO, Bjorck JE: Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 353:611-616, 1999
79. Yusuf S, Gerstein H, Hoogwerf B, Pogue J, Bosch J, Wolffenbuttel BH, Zinman B: Ramipril and the development of diabetes. JAMA 286:1882-1885, 2001
80. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342:145-153, 2000.
81. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U, Flyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359:995-1003, 2002
82. McFarlane SI, Kumar A, Sowers JR: Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease. Am J Cardiol 91:30H-37H, 2003
83. Sharma AM, Janke J, Gorzelniak K, Engeli S, Luft FC: Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension 40:609-611, 2002